Loading…
Vaxcyte, Inc. is projected to rise to $65.85 by 2027, a +13% move from its current price of $58.21. PCVX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $56.70 | $58.20 | $59.75 | -0.01% |
| Jul 14 | $56.08 | $58.20 | $60.39 | -0.02% |
| Jul 15 | $55.61 | $58.19 | $60.89 | -0.03% |
| Jul 16 | $55.22 | $58.19 | $61.31 | -0.04% |
| Jul 17 | $54.87 | $58.18 | $61.69 | -0.05% |
| Jul 18 | $54.56 | $58.17 | $62.03 | -0.06% |
| Jul 19 | $54.27 | $58.17 | $62.34 | -0.07% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $54.27 | $58.17 | $62.34 | -0.07% |
| Week 2 | $52.70 | $58.12 | $64.11 | -0.15% |
| Week 3 | $51.51 | $58.08 | $65.49 | -0.22% |
| Week 4 | $50.52 | $58.04 | $66.66 | -0.30% |
| Week 5 | $49.67 | $57.99 | $67.71 | -0.37% |
| Week 6 | $48.90 | $57.95 | $68.67 | -0.45% |
| Week 7 | $48.20 | $57.91 | $69.56 | -0.52% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Vaxcyte, Inc. is a clinical-stage vaccine innovation company that develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants.
The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc.
in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Vaxcyte, Inc. trades under the symbol PCVX and is currently priced at $60.67 per share, with a market capitalization of $8.76B and a rank of 1006. The stock sits in a price range that the forecast envisions expanding in the coming years, reflecting a longer-term bullish trajectory despite near-term variability.
A major floor 32.1% below — a decisive break under it would weaken the trend.
The nearest floor, 22.0% below — buyers have tended to step in here.
The nearest ceiling, 4.2% above — a clean break opens room to run.
A major ceiling 20.3% above — clearing it would confirm fresh momentum.
Key PCVX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PCVX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $58.88 | Sell | $58.63 | Sell |
| MA 10 | $58.12 | Buy | $57.55 | Buy |
| MA 20 | $54.43 | Buy | $55.49 | Buy |
| MA 50 | $52.49 | Buy | $54.02 | Buy |
| MA 100 | $55.55 | Buy | $53.44 | Buy |
| MA 200 | $50.77 | Buy | $52.21 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 59.12 | Neutral |
| Stoch RSI (14) | 21.31 | Neutral |
| CCI (20) | 68.26 | Neutral |
| Williams %R (14) | -28.24 | Info |
| MACD (12,26,9) | 0.55 | Buy |
| ROC (12) | 12.03 | Buy |
| Bollinger %B (20,2) | 0.73 | Neutral |
| Stochastic %K (14) | 71.76 | Neutral |
| TRIX (15) | 0.49 | Buy |
| Awesome (5,34) | 6.97 | Buy |
| Ultimate (7,14,28) | 55.90 | Neutral |
| Momentum (10) | 4.53 | Buy |
| Aroon Osc (25) | 68.00 | Buy |
| Hull MA (9) | 59.73 | Sell |
| ADX (14) | 24.26 | Buy |
| ATR (14) | 1.47 | Info |
Near term, the technical picture is bullish with RSI(14) at 70, suggesting strong momentum. The 50-day simple moving average stands at $52.52, above the 200-day moving average of $50.37, which supports a positive trend. Key intraday levels are a support at $45.42 and a resistance at $60.67, framing a recent 30-day range from $50.82 to $72.43.
Annualized volatility is 50%, signaling substantial price movement potential in the coming weeks.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $44.85 | $58.21 | $73.24 | 0% | Neutral | |
| $52.62 | $65.85 | $87.05 | +13% | Neutral | |
| $51.52 | $66.20 | $90.70 | +14% | Neutral | |
| $54.38 | $71.44 | $100.65 | +23% | Bullish | |
| $62.97 | $84.36 | $121.68 | +45% | Bullish | |
| $70.07 | $95.54 | $140.67 | +64% | Bullish | |
| $79.24 | $109.84 | $164.73 | +89% | Bullish | |
| $85.35 | $120.15 | $183.23 | +106% | Bullish | |
| $87.78 | $125.40 | $194.20 | +115% | Bullish | |
| $89.71 | $129.97 | $204.17 | +123% | Bullish | |
| $133.65 | $206.32 | $344.13 | +254% | Bullish | |
| $199.18 | $342.80 | $624.05 | +489% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $44.85 | $58.21 | $69.26 | +0.00% |
| August 2026 | $48.36 | $57.01 | $68.97 | -2.07% |
| September 2026 | $48.57 | $57.64 | $70.49 | +1.12% |
| October 2026 | $49.86 | $59.52 | $73.44 | +3.26% |
| November 2026 | $49.46 | $59.33 | $73.75 | -0.33% |
| December 2026 | $48.55 | $58.50 | $73.24 | -1.39% |
Click any year to see its month-by-month PCVX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Vaxcyte, Inc.'s 2026 outlook centres on $58.21, within a $44.85 to $73.24 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, PCVX could reach as high as $87.05, with a base case around $65.85 and support toward $52.62 — roughly +13% from $58.21. A consolidation phase looks the most probable path here.
Expect PCVX to range from $51.52 to $90.70 through 2028. The $66.20 average target implies a +14% move from current prices. That is up +1% on the projected 2027 average. Price action looks broadly range-bound.
The PCVX price prediction for 2029 points to an average of $71.44 (low $54.38, high $100.65) — a potential gain of +23% on today's $58.21. Buyers look set to stay in control over this stretch.
In 2030, PCVX is projected to trade between $62.97 and $121.68, averaging $84.36 — a potential gain of +45% from today's $58.21. That is up +18% on the projected 2029 average. Momentum favours further upside here.
Vaxcyte, Inc.'s 2031 outlook centres on $95.54, within a $70.07 to $140.67 range. That is up +13% on the projected 2030 average. That marks a +64% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, PCVX could reach as high as $164.73, with a base case around $109.84 and support toward $79.24 — roughly +89% from $58.21. Momentum favours further upside here.
Expect PCVX to range from $85.35 to $183.23 through 2033. The $120.15 average target implies a +106% move from current prices. That is up +9% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The PCVX price prediction for 2034 points to an average of $125.40 (low $87.78, high $194.20) — a potential gain of +115% on today's $58.21. Momentum favours further upside here.
In 2035, PCVX is projected to trade between $89.71 and $204.17, averaging $129.97 — a potential gain of +123% from today's $58.21. That is up +4% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Vaxcyte, Inc.'s 2040 outlook centres on $206.32, within a $133.65 to $344.13 range. That is up +59% on the projected 2035 average. That marks a +254% change versus current levels. Momentum favours further upside here.
By 2050, PCVX could reach as high as $624.05, with a base case around $342.80 and support toward $199.18 — roughly +489% from $58.21. Buyers look set to stay in control over this stretch.
Investing $1,000 in PCVX today (≈ 17.179179 PCVX) could be worth
$5,889.02
+$4,889.02 (+489%) by 2050 · US Dollar
Based on the average projected PCVX price of $342.8 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PCVXwould be worth at today's price.
$1,000 invested in PCVX on Jul 10, 2025 (≈ 27.593818 PCVX) would be worth
$1,606.24
+$606.24 (+60.6%) today · 1.61× · US Dollar
Based on a PCVX entry price of $36.24 vs. today's $58.21.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $58.39 | $996.92 | -0.3% |
| 1 month ago | $45.42 | $1,281.59 | +28.2% |
| 3 months ago | $60.88 | $956.14 | -4.4% |
| 6 months ago | $45.84 | $1,269.85 | +27.0% |
| 1 year ago | $36.24 | $1,606.24 | +60.6% |
| All time (5.0y) ago | $22.34 | $2,605.64 | +160.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PCVX forecast.
Our base-case forecast reaches $120.00 around 2033.
Implied market cap at $120.00: $17.33B
The multi-year forecast envisions a rising price path with bullish momentum continuing into the next decade. In 2026 the average price is projected at $60.67 with a neutral sentiment, and by 2027 the average rises to $69.38 (ROI 14.3%, neutral) and 2028 to $69.63 (ROI 14.8%, neutral). By 2029, the average is $75.90 (ROI 25.1%, bullish) and by 2030 an average of $90.79 (ROI 49.6%, bullish).
The sequence continues with 2031 at $102.62, 2032 at $118.74, 2033 at $130.68, 2034 at $135.37, and 2035 at $141.11, all with bullish sentiment and progressively higher ROIs. The forecast projects a substantial rise by 2040 to an average of $226.08 (ROI 272.6%, bullish) with a max of $380.10 and a min of $145.13. By 2050, the average is $379.74 (ROI 525.9%, bullish) with a max of $697.84 and a min of $217.79.
These figures illustrate a long-term bullish trajectory, though they are estimates and not guarantees.
Tap a question to reveal the answer.
The forecast for 2030 shows an average price of $90.79, with a minimum of $67.47 and a maximum of $131.65; ROI is 49.6% and sentiment is BULLISH.
Forecasts indicate a bullish long-term trajectory from 2029 onward, with 2030 average price of $90.79 and ROI of 49.6%, and a 2050 average price of $379.74 with ROI of 525.9%. These are estimates, not guarantees.
Current price is $60.67 and market cap is $8.76B.
Yes. The forecast lists a 2030 maximum of $131.65.
2040: min $145.13, avg $226.08, max $380.10; ROI 272.6%; sentiment BULLISH. 2050: min $217.79, avg $379.74, max $697.84; ROI 525.9%; sentiment BULLISH.
Vaxcyte, Inc. Community Discussion
0Share your Vaxcyte, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.